← Back to headlines
BMO Raises Price Target for Protagonist Therapeutics on Drug Approval
Investment analysts have increased their valuation forecast for Protagonist Therapeutics following regulatory approval for its Mimrylo treatment.
1 Sept, 14:00 — 1 Sept, 14:00
Sources
Showing 1 of 1 sources
